ASCO 2017 | Richter’s syndrome and its impact on CLL patients
Matthew Davids
• 1 Jun 2017
Matthew Davids, MD, MMSc, from the Dana-Farber Cancer Institute, Boston, MA, discusses the poor outcomes of chronic lymphocytic leukemia (CLL) patients who develop Richter’s syndrome upon receiving treatment and describes a multi-institutional study evaluating a cohort of these patients and their remission rates, which were generally low, thereby highlighting a clear unmet medical need for these patients. There does appear to be some promise though, as highlighted by Prof. Davids, since a few patients did achieve complete remission. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
